Welcome to our dedicated page for Viatris news (Ticker: VTRS), a resource for investors and traders seeking the latest updates and insights on Viatris stock.
Viatris Inc. reports developments for a global healthcare company with a portfolio spanning generics, established brands and innovative medicines. News commonly covers quarterly results, guidance, cash deployment, dividends, capital allocation and management changes, alongside product launches and pipeline updates across major therapeutic areas.
Company updates also include scientific presentations and regulatory actions tied to specific medicines and candidates, including Effexor in Japan, ophthalmology programs such as phentolamine ophthalmic solution and RYZUMVI, and an investigational low-dose estrogen combined hormonal contraceptive weekly patch. Viatris was formed through the combination of Mylan and Pfizer's Upjohn business and operates with global centers in the U.S., China and India.
Viatris reaffirms its 2022 guidance for total revenues, adjusted EBITDA, and free cash flow, reporting solid operating momentum despite foreign exchange challenges and inflation impacts. Total revenues stand at $4.08 billion, with U.S. GAAP net earnings of $354 million and adjusted EBITDA of $1.50 billion. The company generated $869 million in net cash from operating activities and $765 million in free cash flow. Year-to-date, Viatris has paid down $2.1 billion of debt ahead of schedule and declared a quarterly dividend of $0.12 per share.
Viatris Inc. (NASDAQ: VTRS) will announce its financial results for Q3 2022 on November 7, 2022, at 8:30 a.m. ET. Key executives, including Executive Chairman Robert J. Coury and CEO Michael Goettler, will host a webcast reviewing the quarterly results and an update regarding the February 28 Investor Event. Investors can access the live call via investor.viatris.com or by calling provided numbers. Viatris, established in November 2020, focuses on providing global healthcare solutions through its extensive portfolio of approved products.
Summary not available.
Viatris Inc. (NASDAQ: VTRS) will participate in the BofA Global Research Global Healthcare Conference on September 15, 2022, in London. The event will feature a fireside chat with CEO Michael Goettler, President Rajiv Malik, and CFO Sanjeev Narula, scheduled for 4:45 p.m. BST / 11:45 a.m. ET. A live webcast will be available at investor.viatris.com, along with an archived version post-event. Viatris, formed in November 2020, aims to enhance global health by providing access to over 1,400 medicines.
Viatris reported total revenues of $4.12 billion with U.S. GAAP net earnings at $314 million and adjusted EBITDA of $1.48 billion. The company generated U.S. GAAP net cash provided by operating activities of $803 million and free cash flow of $719 million in the first half of 2022. Despite facing foreign exchange headwinds, it reaffirms guidance for adjusted EBITDA and free cash flow, while revising total revenues guidance to reflect currency impacts. A quarterly dividend of $0.12 per share was declared, and the company paid down $1.5 billion in debt with a target of $2 billion for the full year.
Viatris Inc. (NASDAQ: VTRS) will announce its second quarter 2022 financial results on August 8 before U.S. market opening. A live webcast will be held at 8:30 a.m. ET on the same day to discuss the results. Viatris, formed in November 2020, offers over 1,400 approved molecules across various therapeutic areas and operates globally with around 37,000 employees. The company's mission is to provide access to high-quality medicines, leveraging its extensive portfolio and global healthcare capabilities.
Viatris Inc. (NASDAQ: VTRS) will participate in the Goldman Sachs 43rd Annual Global Healthcare Conference on June 14, 2022, in Rancho Palos Verdes, CA. CEO Michael Goettler, President Rajiv Malik, and CFO Sanjeev Narula will engage in a fireside chat at 1:20 p.m. PT. A live webcast of the event will be available on investor.viatris.com and an archived version will follow.
Viatris, formed in November 2020, operates globally with a portfolio of over 1,400 approved molecules across diverse therapeutic areas.
Summary not available.
Viatris reported strong first-quarter 2022 results, achieving total revenues of $4.19 billion and U.S. GAAP net earnings of $399.2 million. Adjusted EBITDA stood at $1.59 billion, with free cash flow reaching $1.07 billion. The company confirmed its $600 million new product revenue target and made significant progress on its debt repayment strategy, paying down $840 million of debt. Additionally, a quarterly dividend of $0.12 per share was declared. The ongoing conflict in Ukraine has had limited immediate impact but poses potential future risks.
Viatris Inc. (NASDAQ: VTRS) will announce its Q1 2022 financial results on May 9, 2022, before U.S. market opening. The announcement will be followed by a live webcast at 8:30 a.m. EDT, featuring executives including CEO Michael Goettler and CFO Sanjeev Narula. The company aims to provide insights on its performance since being formed in November 2020, leveraging extensive expertise to deliver high-quality medicines globally.